JP2009518447A - プロテアソームインヒビターと併せたｉｌ６アンタゴニストの使用方法 - Google Patents

プロテアソームインヒビターと併せたｉｌ６アンタゴニストの使用方法 Download PDF

Info

Publication number
JP2009518447A
JP2009518447A JP2008544662A JP2008544662A JP2009518447A JP 2009518447 A JP2009518447 A JP 2009518447A JP 2008544662 A JP2008544662 A JP 2008544662A JP 2008544662 A JP2008544662 A JP 2008544662A JP 2009518447 A JP2009518447 A JP 2009518447A
Authority
JP
Japan
Prior art keywords
antibody
bortezomib
proteasome inhibitor
cell
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518447A5 (enExample
Inventor
ザキ，モハメド
ネメス，ジエフリー
オーロウスキ，ロバート
Original Assignee
セントカー・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントカー・インコーポレーテツド filed Critical セントカー・インコーポレーテツド
Publication of JP2009518447A publication Critical patent/JP2009518447A/ja
Publication of JP2009518447A5 publication Critical patent/JP2009518447A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008544662A 2005-12-09 2006-12-08 プロテアソームインヒビターと併せたｉｌ６アンタゴニストの使用方法 Pending JP2009518447A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09
PCT/US2006/061786 WO2007067976A2 (en) 2005-12-09 2006-12-08 Method of using il6 antagonists with proteasome inhibitors

Publications (2)

Publication Number Publication Date
JP2009518447A true JP2009518447A (ja) 2009-05-07
JP2009518447A5 JP2009518447A5 (enExample) 2009-11-12

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544662A Pending JP2009518447A (ja) 2005-12-09 2006-12-08 プロテアソームインヒビターと併せたｉｌ６アンタゴニストの使用方法

Country Status (15)

Country Link
US (1) US20090022726A1 (enExample)
EP (1) EP1954310A4 (enExample)
JP (1) JP2009518447A (enExample)
KR (1) KR20080072761A (enExample)
CN (1) CN101325969A (enExample)
AR (1) AR057227A1 (enExample)
AU (1) AU2006321610A1 (enExample)
BR (1) BRPI0619498A2 (enExample)
CA (1) CA2632732A1 (enExample)
EA (1) EA014675B1 (enExample)
IL (1) IL191694A0 (enExample)
NO (1) NO20082907L (enExample)
TW (1) TW200803895A (enExample)
WO (1) WO2007067976A2 (enExample)
ZA (1) ZA200805956B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510867A (ja) * 2009-11-13 2013-03-28 オニキス セラピューティクス， インク． 転移抑制のためのペプチドエポキシケトンの使用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
JP5616569B2 (ja) 2004-04-15 2014-10-29 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 酵素阻害のための化合物
BRPI0510802A (pt) 2004-05-10 2007-11-06 Proteolix Inc compostos para inibição de enzima
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
EP3135298B1 (en) * 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
EP3246045B1 (en) * 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
EP2344165A4 (en) * 2008-10-01 2012-12-05 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2464666B1 (en) 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
TW201600110A (zh) * 2009-07-31 2016-01-01 Shin Maeda 癌之轉移抑制劑
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
US20190046497A1 (en) * 2016-02-14 2019-02-14 Yeda Research And Development Co., Ltd. Methods of modulating protein exocytosis and uses of same in therapy
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
AU762373B2 (en) * 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
WO2004071404A2 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510867A (ja) * 2009-11-13 2013-03-28 オニキス セラピューティクス， インク． 転移抑制のためのペプチドエポキシケトンの使用

Also Published As

Publication number Publication date
EP1954310A2 (en) 2008-08-13
NO20082907L (no) 2008-08-26
EP1954310A4 (en) 2009-04-22
AR057227A1 (es) 2007-11-21
ZA200805956B (en) 2009-10-28
WO2007067976A3 (en) 2008-02-14
EA014675B1 (ru) 2010-12-30
US20090022726A1 (en) 2009-01-22
EA200870029A1 (ru) 2008-10-30
KR20080072761A (ko) 2008-08-06
CN101325969A (zh) 2008-12-17
CA2632732A1 (en) 2007-06-14
IL191694A0 (en) 2008-12-29
AU2006321610A1 (en) 2007-06-14
BRPI0619498A2 (pt) 2011-10-04
TW200803895A (en) 2008-01-16
WO2007067976A2 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
US20090022726A1 (en) Method of using il6 antagonists with proteasome inhibitors
US20080081041A1 (en) Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
CN101668531B (zh) 用于治疗免疫病症的联合治疗
US8629257B2 (en) IL-12/p40 binding proteins
US20120275996A1 (en) IL-1 Binding Proteins
US20100221179A1 (en) IL-1 Binding Proteins
US20110165063A1 (en) Il-1 binding proteins
CA2775402A1 (en) Il-1 binding proteins
JP2019534282A (ja) 抗ｉｌ−３３抗体およびその使用
JP2009541374A (ja) Ｃｏｐｄを処置するためのｃｄ２０結合分子
AU2012238334A1 (en) IL-12/p40 binding proteins
MX2008007329A (en) Method of using il6 antagonists with proteasome inhibitors
Schotanus et al. Effects of Monoclonal Antibodies to Specific Epitopes of Rat Interleukin‐1 Beta (IL‐Iβ) on IL‐1β‐Induced ACTH, Corticosterone and IL‐6 Responses in Rats
AU2014200946A1 (en) Combination therapy for treatment of immune disorders
HK1167100A (en) Combination therapy for treatment of immune disorders
HK1167104A (en) Combination therapy for treatment of immune disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120814